Impact News +++ Nouveau Monde Graphite plans to raise capital via stock (SeekingAlpha) +++ NOUVEAU MONDE Aktie -4,89%

ASTELLAS Aktie

>ASTELLAS Aktienkurs

11.515 EUR +3.0% (Tradegate)

Ask: 11.735 EUR / 427 Stück

Bid: 11.505 EUR / 435 Stück

Tagesumsatz: 210 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

ASTELLAS Aktie über LYNX handeln

Intraday

1 Jahr

>ASTELLAS Performance

1 Woche: +1,1%

1 Monat: +9,7%

3 Monate: +18,3%

6 Monate: +35,2%

1 Jahr: +19,2%

laufendes Jahr: +21,0%

>ASTELLAS Aktie

Name:

ASTELLAS PHARMA INC.

Land:

Japan

Sektor:

Gesundheit

ISIN/ Wkn:

JP3942400007 / 856273

Symbol/ Ticker:

YPH (Frankfurt)

Kürzel:

FRA:YPH, ETR:YPH, YPH:GR

Index:

Nikkei225

Webseite:

https://www.astellas.com/

Profil:

Astellas Pharma Inc. is a global pharmaceutical co..
>Volltext..

Marktkapitalisierung:

21084.31 Mio. EUR

Unternehmenswert:

23699.87 Mio. EUR

Umsatz:

11563.66 Mio. EUR

EBITDA:

3186.12 Mio. EUR

Nettogewinn:

719.53 Mio. EUR

Gewinn je Aktie:

0.4 EUR

Schulden:

4267.13 Mio. EUR

Liquide Mittel:

1654.06 Mio. EUR

Operativer Cashflow:

2336.15 Mio. EUR

Bargeldquote:

0.22

Umsatzwachstum:

4.41%

Gewinnwachstum:

110.29%

Dividende je Aktie:

0.43 EUR

Dividendenrendite:

3.57%

Dividendenschätzung:

3.67%

Div. Historie:

29.09.25 - 0.2222064€
28.03.25 - 0.2108112€

>weitere anzeigen...

Insiderhandel:

Suchwörter:

ASTELLAS

Letzte Datenerhebung:

18.12.25

>ASTELLAS Kennzahlen

Aktien/ Unternehmen:

Aktien: 1791.21 Mio. St.

Frei handelbar: 95.74%

Leerverk. Aktien: -

Rückkaufquote: 0.02%

Mitarbeiter: 13643

Umsatz/Mitarb.: 0.8 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: -8.46%

Bewertung:

KGV: 28.47

KGV lG: 21.45

KUV: 1.84

KBV: 2.19

PEG-Ratio: 0.23

EV/EBITDA: 7.44

Rentabilität:

Bruttomarge: 74.65%

Gewinnmarge: 6.22%

Operative Marge: 17.89%

Managementeffizenz:

Gesamtkaprendite: 3.61%

Eigenkaprendite: 7.95%

>ASTELLAS Peer Group

Es sind 52 Aktien bekannt.

>ASTELLAS Chart & Kurs - Tradegate

>ASTELLAS News

18.12.25 - 07:42	Astellas Reports Positive Phase 3 EV-304 Results For PADCEV Combo In Muscle-Invasive Bladder Cancer (AFX)
	NEW YORK CITY (dpa-AFX) - Astellas Pharma Inc. and Pfizer Inc. announced positive topline results from the Phase 3 EV-304 clinical trial (KEYNOTE-B15), evaluating PADCEV (enfortumab vedotin), a Ne......

17.12.25 - 13:30	Pfizer, Astellas post late-stage trial win for Padcev in bladder cancer with Merck’s Keytruda (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

11.12.25 - 00:33	Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium (PR Newswire)
	- Data reflect new insights and precision oncology advancements in portfolio and pipeline - - Cohort results from Phase 2 ILUSTRO study evaluating a zolbetuximab triplet combination regimen in first-line advanced gastric and gastroesophageal junction (GEJ) cancer featured in late-breaking......

05.12.25 - 14:03	Astellas To Present New Data on XOSPATA™ (gilteritinib) Across the FLT3m+ AML Disease Continuum at ASH 2025 Annual Meeting (PR Newswire)
	- Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML - - Findings from the Phase 3 MORPHO trial in the post-transplant maintenance setting and Phase 1/2 VICEROY trial in......

01.12.25 - 03:06	EMA Validates Review Of Astellas′ PADCEV And KEYTRUDA Combination In Bladder Cancer (AFX)
	TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, 4503.T) announced that the European Medicines Agency (EMA) has validated for review a Type II variation application for PADCEV (enfortumab vedotin). ......

22.11.25 - 05:24	Pfizer: FDA Oks PADCEV + Keytruda Combo For Cisplatin-Ineligible Muscle-Invasive Bladder Cancer (AFX)
	KENILWORTH (NJ) (dpa-AFX) - Pfizer Inc. (PFE) and Astellas Pharma Inc. (ALPMY, 4503.T) announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (enfortumab vedotin-ejfv), a N......

30.10.25 - 12:48	Astellas Pharma gives H1 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

30.10.25 - 09:12	Astellas Pharma H1 Net Profit Surges, Revenue Improves; Lifts Annual Outlook (AFX)
	TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY, 4503.T), a Japanese pharmaceutical company, on Thursday reported a surge in net profit for the first half. In addition, the company has revised up it......

22.10.25 - 16:48	Astellas Pharma Announces Encouraging Data From OPTION-VMS Phase IV Study (AFX)
	TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY.PK), Wednesday announced new real-world preliminary data from the OPTION-VMS Phase IV study, a longitudinal, observational study in participants with ......

20.10.25 - 04:36	Pfizer: XTANDI Plus Leuprolide Cuts Death Risk 40% In High-Risk NmHSPC Phase 3 Study (AFX)
	NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and Astellas Pharma U.S. Inc. announced final overall survival results from the Phase 3 EMBARK study evaluating XTANDI (enzalutamide), in combination wi......

20.10.25 - 04:00	Astellas Reports Sustained GA Reduction With Long-Term IZERVAY Treatment In GATHER2 Extension Study (AFX)
	TOKYO (dpa-AFX) - Astellas Pharma Inc. announced the first results from the open-label extension (OLE) of its Phase 3 GATHER2 study, revealing that monthly treatment with IZERVAY (avacincaptad peg......

16.10.25 - 22:03	Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome (GlobeNewswire EN)
	The 2022 Option Agreement between Astellas and Taysha has expired...

15.10.25 - 02:03	Astellas to Present First Real-World VEOZAH™ (fezolinetant) Data at 2025 Annual Meeting of The Menopause Society (PR Newswire)
	TOKYO, Oct. 14, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) due to menopause, will be......

14.10.25 - 10:24	Astellas′ Phase 2 Study GLEAM Study Of Zolbetuximab In Pancreatic Cancer Misses Primary Endpoint (AFX)
	TOKYO (dpa-AFX) - Astellas Pharma Inc. (ALPMY) on Tuesday said the Phase 2 GLEAM study of zolbetuximab in metastatic pancreatic cancer failed to meet its primary endpoint of overall survival (OS).......

09.10.25 - 13:06	Biopharma Leaders Advance the Future of Life Sciences at Veeva Commercial Summit Europe (PR Newswire)
	Industry gathers to explore Veeva AI innovations and exchange ideas with companies including Astellas, Bayer AG, Boehringer Ingelheim, LEO Pharma, Moderna, and MSD BARCELONA, Spain, Oct. 9, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that Astellas, Bayer AG, Boehringer......

09.10.25 - 01:30	Astellas to Present New Data on IZERVAY™ (avacincaptad pegol intravitreal solution) in Geographic Atrophy at AAO 2025 Annual Meeting (PR Newswire)
	Presentations include long-term GATHER2 open-label extension data, real-world treatment patterns on safety, and biomarker insights on geographic atrophy disease progression TOKYO, Oct. 8, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas")......

01.10.25 - 08:03	Astellas To Present Pioneering Advances Across Its Portfolio and Pipeline at ESMO 2025 (PR Newswire)
	- New clinical data across ten accepted abstracts demonstrate significant progress across Astellas' innovative oncology programs - - Results from the EV-303 trial (also known as KEYNOTE-905) in cisplatin-ineligible patients with muscle invasive bladder cancer selected for presentation in......

29.09.25 - 08:03	Astellas Announces Top Management Personnel Change (PR Newswire)
	TOKYO, Sept. 29, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the following changes to its Top Management structure, effective October 1, 2025. Nick Eshkenazi, current Chief Digital & Transformation Officer (CDTO),......

12.08.25 - 13:00	Pfizer, Astellas post late-stage trial win for Padcev with Merck’s Keytruda in bladder cancer (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

12.08.25 - 11:48	Pfizer′s Padcev Plus Keytruda Extends Bladder Cancer Survival (Bloomberg)
	The combination of Padcev, a bladder cancer drug from Pfizer Inc. and Astellas Pharma Inc., and Merck & Co.'s blockbuster immunotherapy Keytruda extended the lives of patients with a hard-to-treat form of the disease....

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer lesen kann, der ist niemals einsam. - Prof. Dr. Walter Jens

Partner: >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram